Eisai Inc., the Nutley-based pharmaceutical subsidiary of Eisai Co. Ltd., named Tricia Brooks vice president and head of office, Government Affairs and Policy.

Brooks will be responsible for developing and leading the government affairs and public policy function; guiding, representing and growing Eisai’s work to create a network of bipartisan relationships with key decision makers that enables the company to build on the Eisai human health care mission to address the needs of people over the course of their lives.

Brooks will also lead the development of federal and state government strategies aligned to the achievement of corporate, disease, and brand objectives.

She will serve as a member of the Eisai Inc. Executive Committee.

“Tricia brings impressive and varied experience in government affairs and policy. We look forward to seeing her leverage her deep relationships in the public policy environment to help us live our commitment to human health care and push past the boundaries of science to deliver life-changing therapies and health-related solutions that matter to people and society,” said Elsai Executive Vice President of Integrity Alex Scott. “Her strong knowledge and a deep understanding of legislative, reimbursement and regulatory processes will be crucial to our policy-focused efforts as we look to innovate together for the benefit of the patients we serve and their families.”

Brooks has mroe than 25 years’ experience in advocacy, lobbying and policy development. She joins Eisai from the role of vice president of government affairs and policy at Ardelyx Inc., where she led the development, implementation, and execution of government affairs and policy strategies for this emerging company as it worked to bring its first marketed product to the United States.

Brooks has also held senior positions across the health care ecosystem, including at the Alliance of Community Health Plans, Novo Nordisk, Biotechnology Industry Organization and the Christopher and Dana Reeve Foundation.

“Eisai is recognized across the industry for its innovative science and perseverance to create life-changing therapies and solutions for patients. It is this dedication, coupled with Eisai’s focus on patients and their families, that perfectly aligns with my approach to how and why we should impact public policy,” said Brooks in her Jan. 25 hiring statement. “I am eager to get started and look forward to working across the organization and disease areas to continue building Eisai’s reputation with policy makers and stakeholders, while helping to effect positive change for patients, their loved ones and those who help them throughout their journey.”

Brooks will lead the Nutley company’s new Washington, D.C., office that will be located at 401 9th St. NW, Suite 740.